SCHEMBL4460174

SCHEMBL4460174

Oc1ccc(OCS)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 5/20 0.52
LMNA P02545 2/20 0.52
HIF1A Q16665 2/20 0.52
CYP1A2 P05177 1/20 0.52
PTGS1 P23219 1/20 0.52
SLC6A2 P23975 1/20 0.52
CYP2C19 P33261 1/20 0.52
PTGS2 P35354 1/20 0.52
SLC6A3 Q01959 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ESR1 P03372 1/20 0.50
ESR2 Q92731 1/20 0.50
APP P05067 2/20 0.48
NR5A1 Q13285 1/20 0.48
DRD2 P14416 1/20 0.42
DRD4 P21917 1/20 0.42
DRD3 P35462 1/20 0.42
PTPN1 P18031 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13215453 0.89 ESR1 (0.58) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL890923 0.86 NQO1 (0.47) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL13215447 0.84 ESR1 (0.52) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL13215445 0.84 ESR1 (0.52) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL13215446 0.78 ESR1 (0.65) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL8452874 0.78 LTA4H (0.56) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL226548 0.78 LTA4H (0.64) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL2473527 0.76 LTA4H (0.68) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL2470706 0.76 NR5A1 (0.75) LTA4HLMNAHIF1ACYP1A2PTGS1
SCHEMBL7867839 0.76 NQO1 (0.39) LTA4HHDAC6APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7767758-B2 Silane functionalized fluoropolymers XEROX CORPORATION (US) 2010-08-03 US disclosed
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
US-20080205950-A1 Silane Functionalized Fluoropolymers XEROX CORPORATION 2008-08-28 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed
EP-1638943-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) 2006-03-29 EP disclosed
WO-2004106307-A2 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2004-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 LTA4H 3441/4885LMNA 3647/4885HIF1A 1053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.